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Tumours can be recognised by CTL and NK cells. CTL recogni-
tion depends on expression of MHC Class I loaded with peptides
from tumour antigens. In contrast, loss of MHC Class I results in
NK activation. In our study a large set of samples from patients
with primary operable invasive breast cancer was evaluated for
the expression of MHC Class I heavy and light by immunohisto-
chemical staining of 439 breast carcinomas in a tissue microarray.
Forty-seven percent (206 of 439) of breast carcinomas were con-
sidered negative for HLA Class I heavy chain (HC10), whereas
lack of anti-b2m-antibody staining was observed in 39% (167 of
424) of tumours, with only 3% of the b2m-negative tumours
expressing detectable HLA Class I heavy chain. Correlation with
patient outcome showed direct relationship between patient sur-
vival and HLA-negative phenotype (log rank 5 0.004). A positive
relationship was found between the intensity of expression of
MHC Class I light and heavy chains expression and histological
grade of invasive tumour (p < 0.001) and Nottingham Prognostic
Index (p < 0.001). To investigate whether HLA Class I heavy and
light chains expression had independent prognostic signiﬁcance,
Cox multivariate regression analysis, including the parameters of
tumour size, lymph node stage, grade and intensity of HC10 and
anti-b2m staining, was carried out. In our analysis, lymph node
stage (p < 0.001), tumour grade (p 5 0.005) and intensity of MHC
Class I light and heavy chains expression were shown to be inde-
pendent prognostic factors predictive of overall survival (p-values
HC10 5 0.047 and b2m 5 0.018).
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Tumours may either fail to stimulate an immune response a
process known as immune ignorance1 or they may elicit innate or
adaptive immunity in a process known as immune editing.2 Major
histocompatibility complex (MHC) may play a pivotal role in
immune-editing as they present peptides that are recognised by
cytolytic T cells. In contrast, if MHC antigens are downregulated
to avoid T cell attack they become susceptible to NK killing.
There are 4 altered HLA Class I phenotypes that are found com-
monly in tumour tissues including: phenotype I or total HLA loss
(9–52%) that result from interference with b2m synthesis trans-
porter associated with antigen processing (TAP) or structural
defects in MHC genes; phenotype II or loss of HLA haplotype that
can result from chromosomal nondisjunction or mitotic recombi-
nation; phenotype III or loss of HLA locus expression e.g., HLA-
A (3–19%); and HLA-B (5–19%), probably with a mechanism of
transcriptional. Phenotype IV or HLA allelic loss (15–51%) that
such allelic loss might result from mutations or partial deletions of
HLA Class I genes.3
Previous studies have demonstrated that HLA Class I antigens
are downregulated in tumour tissues of patients diagnosed as hav-
ing breast carcinomas.4–9 MHC alterations on the cell surface of
tumours may be an early event or the effect of a multi-step process
during carcinogenesis.10 Moreover, loss of expression of MHC
Class I antigens is observed commonly in malignant tumours3,11
and has been considered one of the mechanisms for escape from
cytotoxic T cells.12 Some rare tumour types, however, have shown
increased expression of HLA Class I, particularly those derived
from tissues with weak or normal HLA Class I expression.11 Few
studies have examined the prognostic signiﬁcance of HLA Class I
expression in cancer. In those studies, loss of HLA Class I mole-
cules has been associated with poor degree of differentiation,
aggressiveness and metastatic potential.8,9,11,13,14 To our knowl-
edge, however, there has been no previous study examining
whether there is any prognostic signiﬁcance of HLA Class I loss
on a large number of parafﬁn embedded invasive breast carcino-
mas. To analyse haplotype or allelic loss on parafﬁn sections of
tumours it would be necessary to know the HLA type of all of the
patients. This is not possible, however, in a retrospective study as
many of these patients are no longer alive. In contrast, antibodies
to polymorphic heavy chains and b2m are available allowing us to
study complete loss of MHC Class I.
To obtain more insight into the prognostic value and mecha-
nisms that tumour cells use to escape from immune system, we
analysed HLA Class I expression in a large series of breast cancer
tissue arrays using a monoclonal antibody to the polymorphic
heavy chain (HC10) and a polyclonal anti-b2 microglobulin anti-
body. Expression of HLA heavy and light chains was then associ-
ated with various clinicopathological parameters and patient out-
come. Our study group consisted of 439 primary operable breast
cancer with a mean follow up of 7 years.
Material and methods
Patients and tumour characteristics
The original study group consisted of 439 primary operable
invasive breast carcinoma from patients 27–70 years of age
(median 5 54 years) diagnosed between 1987–1992 and obtained
from the Nottingham Tenovus Primary Breast Carcinoma Series.
Patient characteristics, including age and menopausal status, were
also collected and information on local, regional and distant recur-
rence and survival was also retrieved from a prospective database
(Table I). Patients were followed up at 3-month intervals initially,
then 6-month intervals, then annually for a median period of 83
months with a mean survival of 77 months (1–151 months).
Patient management was based on tumour characteristics by
calculating the Nottingham Prognostic Index (NPI). Women with
an NPI score 3.4 received no adjuvant therapy, those with a NPI
score >3.4 received tamoxifen if ER positive (6Zoledex if pre-
menopausal) or classical cyclophosphamide, methotrexate and
5-ﬂuorouracil (CMF) if ER negative and ﬁt enough for chemo-
therapy to be appropriate.
Tissue preparation
Breast cancer tissue microarrays were prepared as described
previously.15 Each case was sampled in 3 copies, each containing
one sample from a different region of the tumour.16 Specimens
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from 160 tumours could not be included in the study because of
lack of tumour in the arrayed sample (due to sampling error or
previous sectioning).
This is a well characterized series of primary operable breast
cancer treated in a uniform manner and has been used to study a
wide range of potential prognostic factors and markers including
CD59,16 CD5517 and CD46 expression.18 Tumour characteristics,
including histological grade,19 tumour type,20 vascular invasion,21
menopausal status,22 tumour size, lymph node stage and Notting-
ham Prognostic Index23 are assessed routinely and recorded in a
database. The Nottingham Prognostic Index (NPI) score was cal-
culated for each patient based on the following equation: NPI 5
0.2 3 tumour size (cm) 1 grade (1–3) 1 lymph node stage (1–3).
This index predicts survival of patients with invasive breast cancer
and is utilised clinically in 3 groups: good (NPI 3.4), moderate
(3.41 < NPI 5.4) or poor (NPI >5.4) prognosis according to the
score obtained.
Antibodies
The mouse mAb HC10 (provided by Professor H. Ploegh, Har-
vard Medical School, USA) recognizes free (non ligand associ-
ated/non-B2m associated) human HLA Class I heavy chains with
preferential binding to HLA-B and HLA-C alleles.24 The anti-
heavy chain mAb HC10 (IgG2a) reacts with denatured Class I
antigens and showed strong reactivity in Western blots and con-
ventional light microscopical analysis of formalin-ﬁxed, parafﬁn-
embedded sections. This mAb precipitated 4 bands of molecular
mass 78–105 kDa and additional higher molecular mass material,
seen by nonreducing SDS-PAGE,24,25 HC10 recognizes an epitope
in the domain of unfolded HLA-B and -C heavy chains that are
not assembled with b2m.
26 In contrast b2m is essential for the
structural stability and optimal function of Class I molecule,27 and
is invariant and therefore independent of allelic variants.3,14,28 The
polyclonal rabbit-anti-b2-microglobulin (Dako, Cambridge, Ely,
UK) recognizes the light chain of MHC Class I molecule.
TABLE I – CORRELATION OF HLA EXPRESSION IN INVASIVE BREAST CARCINOMA WITH CLINICOPATHOLOGICAL PARAMETERS (PEARSON v2)
Tumour and patient characteristics Proportion % (n)
Intensity of staining
(p-value)
Percentage of cells stained
(p-value)
HC10 Anti-b2m HC10 Anti-b2m
Age (years)
<40 8 (39)
41–50 28 (150) 0.452 0.19 0.072 0.341
51–60 36 (193)
>61 28 (151)
Menopausal status (% of recorded cases)
Pre-menopausal 36 (184/507) 0.567 0.765 0.625 0.266
Post-menopausal 64 (322/507)
Histological Grade
Grade 1 21 (111) <0.001 <0.001 <0.001 <0.001
Grade 2 35 (186)
Grade 3 44 (236)
Lymph node status
LN negative 64 (340) 0.223 0.145 0.682 0.216
LN positive 36 (193)
Tumour size (mm)
<10, 11–20, 21–30, 31–40, 41–50 NA1 0.285 0.197 0.464 0.093
NPI2
Good 35 (181)
Moderate 55 (285) <0.001 <0.001 <0.001 0.003
Poor 10 (55)
Tumour type3
Excellent 6 (31)
Good 21 (113) <0.001 <0.001 <0.001 <0.001
Moderate 12 (64)
Poor 61 (325)
Vascular invasion
None or probable 71 (370) 0.615 0.149 0.515 0.3
Deﬁnite 29 (154)
Distant metastases
Absent 88 (470) 0.027 0.028 0.045 0.032
Present 12 (63)
Any recurrence
Absent 77 (409) 0.242 0.141 0.214 0.1
Present 23 (124)
Regional recurrence
Absent 91 (484) 0.007 0.017 0.018 0.028
Present 9 (49)
Local recurrence
Absent 90 (480) 0.885 0.545 0.268 0.616
Present 10 (53)
Overall survival — 0.004 0.021 0.004 0.072
1NA, none applicable.–2NPI (The Nottingham Prognostic Index) is an integrated prognostic index used to predict patient survival for women
with invasive breast cancer based on tumour size, lymph node stage and tumour grade. It is often clinically utilised in three groups: good (3.4),
moderate (3.41–5.4), and poor prognosis (>5.4)–3Tumour sections were classiﬁed in four prognostic type groups as described previously.36
Excellent prognosis type (>80% 10-year survival) includes tubulo-lobular, tubular, mucinous and invasive cribriform carcinoma. Good prognosis
types (60-80% 10-year survival) includes tubular mixed, mixed ductal with special type and alveolar lobular carcinoma. Moderate prognosis
types (50-60% 10-year survival) includes classical lobular, medullary, atypical medullary and lobular mixed carcinoma. Poor prognosis types
(50% 10-year survival) includes ductal NST, solid lobular, mixed ductal and lobular carcinoma.
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Immunohistochemistry
Sections 4-lm thick were cut and stained using a standard avi-
din–biotin complex method as described previously.17 Microwave
pre-treatment was carried out in citrate buffer (pH 5 6.0) 10 min
at high power followed by 10 min at low power to retrieve antige-
nicity for staining of sections with HC10, whereas no pre-treat-
ment was needed for staining of b2m, based on manufacturer’s
recommendations. The primary antibodies were incubated on the
slides for 1 hr with the optimal dilution found to be 1:200 (HC10)
and 1:3,000 (anti-b2m).
FIGURE 1 – HLA heavy chain (HC10) expression. Immunohistochemical detection of HLA Class I heavy chain (HC10) in normal mammary
epithelium and invasive carcinoma. (a) Normal epithelium of ducts and inﬂammatory cells consistently express HLA. (b) Lack of staining of
tumour cells with strong staining of lymphocytes. (c) weak and (d) moderate staining of HC10. (e) Strong staining of invasive breast tumours.
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Negative controls, consisting of normal swine serum (NSS)
(Harlan Sera Lab, UK) instead of primary antibody, conﬁrmed the
speciﬁcity of the staining. Breast tumours that were associated
strongly MHC Class I immunopositive inﬂammatory cells were
used as internal positive control.
Many studies have shown that, contrary to expectations, tissue
heterogeneity does not negatively inﬂuence the predictive power
of the TMA results.29,30 To assess heterogeneity of the immuno-
reactivity with HC10, a pilot study of 20 cases were examined on
full size tissue sections. A comparison of tissue array and original
full size tissues showed similarity in intensity and the area of posi-
tive of staining.
Evaluation of immunostaining
All of immunostained tissue arrays were evaluated using a
semi-quantitative system by one author (Z.M.) in a coded manner
without knowledge of the clinical and pathological parameters of
the patients. The obtained results were conﬁrmed by 2 observers
(Z.M. and S.E.P.) using a multi-headed microscope and, in difﬁ-
cult cases, a consensus was achieved. The intensity of the staining
was scored on a scale as 0 (absent), 1 (weak), 2 (moderate) or 3
(strong). The percentage of tumour cells showing positive staining
was also assessed semi-quantitatively as 1 (<25%), 2 (25–50%), 3
(51–75%) or 4 (>75%). In addition the histochemical score (H
score) of immunoreactivity was obtained by multiplying the inten-
sity and percentage scores.31 The histochemical score were sub-
grouped into 3 groups of equal range for analysis and a score of
<100 was considered weak, 100–200 was moderate and 201–300
was strong.
Statistical analysis
Statistical analysis of data was carried out using the SPSS pack-
age (version 11 for Windows, Chicago, IL). The signiﬁcance of
associations was determined by means of the Pearson R-test or
Pearson v2 test. In survival analysis, Kaplan-Meier curves were
derived and the statistical signiﬁcance of differences between the
survival of groups with different HLA Class I expression was
determined using the log-rank test. Survival was censored if
the patients were still alive or died from other causes. Cox regres-
TABLE II – INTENSITY OF EXPRESSION OF HLA CLASS I HEAVY
AND LIGHT CHAINS
Immunohistochemical score
% Tumours (n)
HC10 Anti-b2m Ab
None 47 (206) 39 (167)
Weak (1) 34 (150) 36 (153)
Moderate (11) 11 (48) 16 (66)
Strong (111) 8 (35) 9 (38)
Total (n) 439 424
Signiﬁcant association was found between expression of HC10 and
anti-b2m (p-value 5 0.001).
FIGURE 2 – b2-Microglobulin expression in invasive breast carcinoma. (a) No staining of tumour cells. (b) Weak and (c) moderate staining of
breast carcinomas with b2-m. (d) Strong staining of invasive breast tumours.
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sion analysis was used for multivariate analysis to allow the
comparison of the effects of several different factors on survival.
p-values < 0.05 were identiﬁed as statistically signiﬁcant.
Results
Co-expression of MHC Class I light and heavy chains
in breast carcinomas
Only 439 of 539 arrayed samples contained sufﬁcient tumour
cells for assessment by HC10, whereas for b2m staining fewer
samples (424/539) contained adequate tumour cells. Difference in
number of cases in 2 series is due to tissue damage, either tissue
loss or inadequate tumour tissue, a problem associated with tissue
microarrays. Samples (113 of 539) contained stroma and inﬂam-
matory inﬁltrating cells. Inﬂammatory cells including lympho-
cytes, exhibited strong positive staining indicating the success of
the immunohistochemical technique (Fig. 1a). Non-malignant
breast tissues adjacent to carcinoma often showed strong expres-
sion of HLA heavy chain (Fig. 1a) as well as b2 m, however, con-
siderable variations occurred in breast carcinomas. Forty-seven
percent (206 of 439) breast carcinomas were considered negative
for HC10, 45% (198) showed a reduction in the level of expres-
sion (34% weak and 11% moderate staining), whereas only 35
(8%) of breast tumours exhibited strong immunoreactivity in the
cell membrane (Table II, Fig. 1b–e). Similarly, 39% (n 5 167) of
tumours lost b2 m in the cell surface, 52% exhibited a reduction
(36% weak and 16% moderate), whereas only 9% (n 5 38) of
tumours showed strong intensity (Table II, Fig. 2a–d). Expression
of HC10 and b2m in the strong positive tumours was usually more
intense than the adjacent non-malignant epithelium. Moreover,
variable percentage of positive tumour cells was observed among
239 breast carcinomas detected with HC10, 115 (26%) showed
<25% positive tumour cells, whereas 9% (41) of cases showed
extensive expression of HC10 (>75% positive tumour cells; Table
III). In the same way, among 257 breast tumours detected with
b2 m, 16% (66) showed <25% positive tumour cells, whereas
11% (49) of cases showed extensive expression (>75% positive
tumour cells; Table III).
A signiﬁcant association was found between HC10 staining and
b2 m staining (p < 0.001) for intensity and percentage. From 423
tumours analysed independently only 3% of b2 m negative
tumours stained positive for HLA Class I heavy chains (Tables
II,III).
Association of MHC Class I light and heavy chains expression
with clinicopathological characteristics
The association between expression of MHC Class I (HC10 and
b2m) and different prognostic parameters (histological grade,
tumour type, vascular invasion, lymph node stage, tumour size
and Nottingham Prognostic Index), patient characteristics (age
and menopausal status) and outcome (overall survival and devel-
opment of distant metastases, local and regional recurrence) was
investigated in breast carcinomas (Table I).
A positive relationship was found between the intensity of
MHC Class I light and heavy chains expression and histological
grade of invasive tumour (p < 0.001, Table I); a high level of
expression was more often found in histological Grade 3 tumours
compared to Grade 1 lesions (Table IV). It was also found that
expression of HC10 and b2m was related signiﬁcantly to Notting-
ham Prognostic Index (p < 0.001, Table I), i.e., loss of MHC
Class I heavy chain was more often found in tumours from
patients in the good prognosis group compared to poor prognosis
group patients (Table IV).
Moreover, the intensity of MHC Class I heavy and light chains
was associated with histological tumour type group (p < 0.001,
Table I), i.e., absent of staining was more often seen in excellent
prognosis type tumours (tubulo-lobular, tubular, mucinous and
invasive cribriform) compared to poor prognosis types (ductal/
NST, solid lobular, lobular mixed or mixed NST and lobular can-
cers; Table IV).
In particular, there was an association between intensity of
MHC Class I expression and patient outcome, i.e., a strong inten-
sity of HLA expression was correlated signiﬁcantly with the
development of distant metastasis (HC10 and b2 m, p 5 0.02) and
of regional recurrence (HC10: p 5 0.007 and b2 m: p 5 0.017;
Table I). Similarly, a signiﬁcant positive correlation was observed
between the percentage of MHC Class I light and heavy chains
positive tumour cells and histological grade (p < 0.001), NPI
group (HC10: p < 0.001 and b2m: p 5 0.003), tumour type group
(p < 0.001), development of distant metastasis (HC10: p 5 0.045
and b2m: p 5 0.032) and regional recurrence (HC10: p 5 0.018
and b2 m: 0.028; Table I).
In contrast, no association was demonstrated between expres-
sion of MHC Class I light and heavy chains on these invasive
breast carcinomas and the absence or presence of vascular inva-
sion, local recurrence, lymph node stage, menopausal status or
patient age at time of diagnosis (Table I).
Analysis of survival in relation to MHC Class I light
and heavy chains
Kaplan-Meier analysis on these series of breast cancer patients,
with mean follow-up of 7 years, demonstrated signiﬁcant differen-
ces in the overall survival between the patients group with com-
TABLE III – PERCENTAGE OF HLA CLASS I HEAVY AND LIGHT
CHAINS POSITIVE TUMOUR CELLS
% HLA positive cells classiﬁed in 4 groups
% Tumours (n)
HC10 Anti-b2m Ab
None 47 (206) 39 (167)
<25% positive 26 (115) 16 (66)
25–50% positive 8 (33) 15 (63)
51–75% cells 10 (44) 19 (79)
>75% cells 9 (41) 11 (49)
Total (n) 439 424
Signiﬁcant association was found between proportion of tumour
cells stained with HC10 and anti-b2m (p-value 5 0.001).
TABLE IV – ASSOCIATION BETWEEN INTENSITY OF HLA HEAVY
CHAIN (HC10) EXPRESSION AND HISTOLOGICAL GRADE, DISTANT
METASTASIS, REGIONAL RECURRENCE, NOTTINGHAM PROGNOSTIC
INDEX AND TUMOUR TYPE (PEARSON v2)
Prognostic factors n
Intensity of HC10 expression (%)
p-value
None Weak Moderate Strong
Histological grade
Grade 1 90 58 (64) 26 (29) 4 (5) 2 (2)
<0.001Grade 2 151 84 (56) 49 (32) 11 (7) 7 (5)
Grade 3 196 64 (33) 73 (37) 33 (17) 26 (13)
Distant metastasis
Absent 384 190(50) 124 (32) 42 (11) 28 (7)
0.027
Present 55 16 (29) 26 (47) 6 (11) 7 (13)
Regional recurrence
Absent 401 197 (49) 134 (33) 42 (11) 28 (7)
0.007
Present 38 9 (24) 16 (42) 6 (16) 7 (18)
NPI
Good 148 90 (61) 48 (32) 6 (4) 4 (3)
<0.001Moderate 233 94 (40) 83 (36) 34 (15) 22 (9)
Poor 47 22 (47) 12 (25) 7 (15) 6 (13)
Tumour type
Excellent 18 14 (78) 3 (17) 1 (5)
<0.001
Good 100 62 (62) 30 (30) 8 (8)
Moderate 51 26 (51) 16 (31) 5 (10) 4 (8)
Poor 265 102 (39) 98 (37) 35 (13) 30 (11)
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plete loss of MHC Class I light and heavy chains (no staining) and
MHC Class I light and heavy chains positive tumours (weak, mod-
erate or strong staining, Log-rank test for HC10 and b2m: 0.0047
and 0.021, Fig. 3a,b). As can be seen in Figure 3a,b, patients
whose breast tumours lost MHC Class I showed a more favourable
outcome than those tumours with immunohistochemically detect-
able expression of MHC Class I. Similar results was found for the
percentage of cells expressing HC10 and patient survival, indicat-
ing that the cumulative survival rate of the patients with absent or
a low percentage of HC10 positive cells (<25%) was signiﬁcantly
higher than that for patients with >25% positive tumour cells (p
5 0.0047, Fig. 3c). In contrast, there was no signiﬁcant associa-
tion between the percentage of cells expressing b2m and these
groups of patients (p 5 0.072, Fig. 3d). Brieﬂy, patients with car-
cinomas exhibiting a lower level of HLA expression achieved lon-
ger survival times.
Multivariate analysis
To investigate whether HLA expression had independent prog-
nostic signiﬁcance, Cox multivariate regression analysis, includ-
ing the parameters of tumour size, lymph node stage, grade and
intensity of HC10 and b2m expression, was carried out. In this
analysis, lymph node stage (p < 0.001), tumour grade (p 5
0.005) and intensity of MHC Class I light and heavy chains
expression were shown to be independent prognostic factors pre-
dictive of overall survival (p-values for HC10 and b2m are:
FIGURE 3 – HLA expression and overall survival. Kaplan-Meier analysis showing the overall survival of breast cancer patients according to
the HLA staining with HC10 and b2 microglobulin (a,b) and the semi-quantitatively assessed percentage of positive cells (c,d). Overall survival
of HLA negative cells (no staining of HC10 and b2 microglobulin) was better than that of positive tumours (weak, moderate or strong staining,
p-values for HC10 and b2 are 0.0047 and 0.021; a,b). Similarly, patients with absent or a low percentage of HC10 positive cells (<25%) showed
signiﬁcantly longer survival times than patients with >25% positive tumour cells (p 5 0.0043, c), whereas it was not signiﬁcant for percentage
of b2m positive cells (d)
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0.047 and 0.018). The percentage of cells expressing b2m was
also found to be of independent prognostic signiﬁcance (p 5
0.047, Table V).
Discussion
We found weak expression or absence of MHC Class I mole-
cules in the majority of breast carcinomas studied. In 47% of pri-
mary breast carcinomas no staining for MHC Class I was
observed, similarly lack of staining for b2m was observed in 39%
of tumours. Importantly analysis of individual tumours indicated
that concordant results were obtained using antibodies to either
Class I heavy chain (HC10) or b2m, with only 3% of b2m negative
tumours showing any expression of MHC Class I heavy chain.
Conversely only 8% of tumours stained positively for MHC Class
I but were absent for b2m expression. This supports earlier studies
on parafﬁn embedded breast carcinomas that showed a good corre-
lation between b2m and heavy chain expression
8 with only 4 of 56
(7%) b2m negative tumours staining for cytoplasmic expression of
free MHC Class I heavy chain.32 A similar lack of expression of
HLA Class I has been reported in a range of tumours including
breast carcinomas.3,8–14,33
Although both haplotype loss and allelic loss of HLA can have
profound consequences for T cell recognition, our study only
addressed the issue of total HLA loss. There are several steps
involved in HLA- Class I expression and any of these could poten-
tially be defective leading to complete loss in tumour cells.
Two types of defects, (i) mutations in the HLA-Class I genes or
abnormal regulation of their expression and (ii) abnormal antigen
processing such as TAP (transporter associated with antigen proc-
essing) or tapasin loss have received the most attention.12 In a
recent study on breast tumours it was shown by RT-PCR and bio-
chemical analysis that loss of HLA Class I expression is associ-
ated predominantly with post-transcriptional regulation of b2m.
34
This may also be a result of dedifferentiation or oncogene ex-
pression.
Hormone receptor status has a high prognostic value in breast
cancer and could possibly have an inﬂuence on MHC Class I
expression as it can be induced on breast cancer cell lines by expo-
sure to oestrogen.35 There was, however, no correlation with oes-
trogen receptor status and HLA expression in our study data (data
not shown). There was a good correlation between histological
grade, distant metastases, Nottingham Prognostic Index, tumour
type and recurrence and the level of expression of MHC Class I
heavy and light chains. Furthermore this was translated into a
direct relationship between patient survival and HLA expression.
These results were unexpected as previous studies had suggested
that loss of Class I MHC expression could lead to escape from T
cell recognition and a higher probability of disease recurrence.33
This correlation was only signiﬁcant for node negative patients
and did not correlate with any clinicopathological parameters in a
much smaller series of breast tumours (n 5 187) that only
included inﬁltrating ductal or lobular carcinomas. Our study has
utilised tissue microarrays that are constructed from small repre-
sentative areas of tumour tissue from multiple blocks of 439 breast
tumours of all types. Heterogeneity arising from this sampling has
been shown to be overcome by staining a large number sam-
ples.29,30 We also addressed this issue by staining of 20 original
full size tissue sections and observed complete concordance with
tissue array results. Several other studies have failed to show any
correlation between HLA-expression and patient prognosis but
most of these studies have analysed small numbers of breast
tumours with short clinical follow up. This is the largest study of
breast tumours with good long-term follow-up and shows that loss
of MHC Class I expression is associated with a good prognosis.
This may be correlated with the recent ﬁnding that MHC Class I
expression is associated with expression of the proapoptotic bax
gene and inversely correlated with expression of the anti-apoptotic
bcl-2 gene.32 Loss of MHC Class I may therefore be associated
with an increased resistance to apoptosis. Alternatively immune
surveillance by T cells may result in tumour escape by downregu-
lation of MHC molecules a process known as ‘‘immune editing.’’2
This loss of MHC I may make the tumours more susceptible to
NK killing and result in a better prognostic outcome
Our study shows that on a large series of breast tumours with
long-term clinical follow-up there is a selective loss of expression
of MHC Class I heavy and light chains that is related to improved
prognosis. This loss may be a consequence of dedifferentiation as
expression correlated with tumour stage and grade although loss
of MHC heavy and light chains was shown to be an independent
prognostic factor. Alternatively it may be due to immunosurveil-
lance that in some patients selects against the more aggressive
tumours leaving the more indolent HLA negative tumours to grow
through. The growth of these tumours may then be further con-
trolled by NK cells. In contrast tumour cells may downregulate
speciﬁc HLA alleles protecting them from speciﬁc T cell attack
while not making then susceptible to NK recognition. This issue
was not addressed in our study.
In conclusion, loss of MHC heavy and light chains has been
shown to be an independent indicator of good prognosis in breast
tumours. It could be added to the other independent prognostic
factors to help further stratify patients for adjuvant therapy.
Patients expressing HLA could be candidates for aggressive che-
motherapy as they have a poor predicted outcome. Alternatively
they may be candidates for cancer vaccines that stimulate new
cytotoxic T cell responses. In contrast patients lacking Class I
HLA may be appropriate for monoclonal antibody therapy such as
Herceptin as lack of HLA would enhance NK killing by antibody
dependent cellular cytotoxicity (ADCC).
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